Jazz lines up $1B for lung cancer drug, making oncology focus clear
While the Irish biopharma is best known for its sleep drugs, this deal adds to a pipeline that shows Jazz’s ambitions are in cancer.
Related Articles
Apellis shares sink on reports of rare side effects with new vision loss drug
An organization of retinal specialists flagged six cases of severe eye inflammation from commercial use of Syfovre. Apellis says the drug’s safety profile is consistent…
Lilly Alzheimer’s drug slowed disease by roughly half a year, new results show
New data presented Monday at a research conference support Lilly’s case for donanemab, while documenting its risks in greater detail.
With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy
The agency granted a long-awaited clearance on Thursday, but unexpected aspects of the hemophilia treatment’s label had some investors worried about its commercial prospects.
FDA approves new ALS medicine in precedent-setting decision
Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the…
Verve partners with Lilly on gene editing therapy for heart disease
Lilly will pay the genetic medicine specialist $60 million upfront to work together on a treatment targeting a risk factor known as Lp(a).
Digital health funding holds steady in Q1 after year of decline
The sector defied trends seen in the larger venture capital environment, where funding continues to fall. But investment is still at years-low levels.
J&J antibody drug combination shows promise in multiple myeloma
A pair of dual-acting antibodies displayed early potential to become a new type of drug regimen for the blood cancer, but led to a high…
(2) The Talamo Topline v1.9: ASCO, Oncology, and More Oncology | LinkedIn
This week on “The Talamo Topline” eNewsletter we anxiously skip over this Memorial Day Weekend (sorry!) and preview what is one of the most exciting…
The Talamo Topline v1.8: Med Comms, ASCO, Energy Bus | LinkedIn
This week of “The Talamo Topline” eNewsletter spends more time in the field of innovation – especially when it comes to the healthcare industry. We…
AbbVie cancer drug sales fall as AstraZeneca competitor gains ground
Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.
